Ocugen CFO Buys Into the Dip as $130M Convertible Note Funds a Trio of Clinical Catalysts

Ocugen CFO invests €25,830 as company secures $130M funding, reshuffles management, and advances three gene therapy pipelines toward Q3 milestones. Stock down 55% from high.

The chief financial officer of Ocugen has put her own money on the line at a moment when the stock is trading more than 50% below its 52-week high. Treerita Essalima Johnson-Greene purchased 21,000 shares on June 17 for roughly €25,830, a transaction that carried the market price near €1.23 at the time. The shares have since slipped to €1.06, leaving the insider bet looking bold against a backdrop of persistent technical weakness.

That insider vote of confidence arrives as Ocugen reshuffles its executive ranks and locks down long-term financing. Dr. Mohamed Genead, who had been serving as interim chief medical officer since May, has taken the role on a permanent basis. Kirsten Castillo and Satish Chandran have also joined the board of directors. The management overhaul coincides with the closing of a $130 million convertible note that extends the company’s cash runway into 2028. Part of the proceeds went to retiring older debt, freeing up resources for the coming wave of clinical studies.

Three Pipeline Countdowns

The personnel moves and fresh capital are all aimed at a concentrated period of regulatory and clinical milestones before the end of September. First up is OCU400, a modifier gene therapy for retinitis pigmentosa. Ocugen expects to begin a rolling submission in the third quarter after fully enrolling the phase 3 study with 140 patients; top-line data are due in early 2027. OCU410, a therapy for dry age-related macular degeneration, will soon launch its own pivotal phase 3 trial. Earlier-stage data showed lesion growth slowed by 31% compared with controls. Meanwhile, Ocugen plans to release a clinical update on OCU410ST within the next three months, covering 24 patients with Stargardt disease.

Cash Position Strengthens Despite Wider Losses

Ocugen’s first-quarter earnings, released in early May, showed total operating costs swelling to $19.4 million from $16.0 million a year earlier, with R&D spending accounting for $11.3 million of that figure. The net loss came to $0.06 per share. On the balance sheet, cash and equivalents stood at $32.2 million at the end of March—up from $18.9 million at year-end 2025. After the recent capital raise and debt repayment, management now expects available funds of roughly $112.1 million, enough to cover operations into 2028. If Janus Henderson exercises additional warrants, that figure could rise by another $15 million.

Technical Picture Still Bleak

The stock has been unable to shake its downtrend even as fundamental news improves. At €1.06, the shares trade about 55% below the 52-week high of €2.35 hit in mid-March. The relative strength index sits at 38.5, hovering near oversold territory but not yet there. Both the 50-day and 200-day moving averages remain overhead, with the stock roughly 18% and 20% below those levels, respectively. The shares climbed 3.21% to €1.09 on the day the permanent CMO was announced, but the rally was modest for a stock that typically moves 42% in either direction over a given month.

The quarter ahead will test whether the market can look past the price weakness and focus on the pipeline. Ocugen is scheduled to present its modifier gene therapy platform at investor and industry conferences in June, giving management a chance to tell the story directly to analysts. With the CFO already signaling her conviction through a personal purchase, the next few months will determine whether the broader market follows suit.